Catecholaminergic polymorphic ventricular tachycardia is a rare devastating lethal inherited disorder or sporadic cardiac ion channelopathy characterized by unexplained syncopal episodes, and/or sudden cardiac death (SCD), aborted SCD (ASCD), or sudden cardiac arrest (SCA) observed in children, adolescents, and young adults without structural heart disease, consequence of adrenergically mediated arrhythmias: exercise-induced, by acute emotional stress, atrial pacing, or β-stimulant infusion, even when the electrocardiogram is normal. The entity is difficult to diagnose in the emergency department, given the range of presentations; thus, a familiarity with and high index of suspicion for this pathology are crucial. Furthermore, recognition of the characteristic findings and knowledge of the management of symptomatic patients are necessary, given the risk of arrhythmia recurrence and SCA. In this review, we will discuss the concept, epidemiology, genetic background, genetic subtypes, clinical presentation, electrocardiographic features, diagnosis criteria, differential diagnosis, and management.
Familial occurrence: ≈30% of cases.
Inheritance may be autosomal dominant (AD) (mutations of the cardiac Ryanodine receptor gene (RyR2)) or recessive associated with mutations in the gene encoding the cardiac isoform of calsequestrin, with high penetrance.
| Genetic types
CPVT has been mapped on chromosomes 1, 7, 14, 4, and 17.
Genetic analysis identifies two main groups and related entities:
1. With mutation or juvenile 2. Sporadic or nongenotyped: These are predominantly women and become symptomatic later in life. Incidence: ≈30%; M/F ratio: F>M;
Inheritance: sporadic or gene-negative CPVT; Onset of symptoms: >20 years. (Figure 1) 
CPVT-related entities

| CPVT with mutation: Characteristics
| CPVT1
Mutations: RyR2 gene. This is the largest known ion channel in the human genome and is responsible for Ca 2+ regulation in the cardiomyocyte (Priori & Chen, 2011) . More than 200 gain-offunction RyR2 variants have been described or to a lesser extent, lossof-function RYR2 mutations exist, but instead underlie an arrhythmia syndrome distinct from CPVT (Roston, Sanatani, & Chen, 2017 ), short-coupled torsades de pointes (TdP) (Fujii et al., 2017) and idiopathic ventricular fibrillation (IVF) (Paech et al., 2014) . Additionally, RyR2 is linked to left ventricular noncompaction (LVNC) (Ohno et al., 2014) . A structural phenotype related to RYR2 exon 3 deletion has been described in an unrelated patient (Campbell, Czosek, Hinton, & Miller, 2015) . Currently, it is not known whether larger deletions of RyR2 are likely to manifest in structural heart disease. Some RyR2 mutations may be benign polymorphisms, and variants of unknown significance in RyR2 are common (Roston et al., 2015) , making it difficult to link rare structural phenotypes to RyR2. Mutations in RyR2 produce altered Ca 2+ homeostasis leading to arrhythmogenic right ventricular cardiomyopathy type 2 (ARVC2) and CPVT (Laitinen, Swan, & Kontula, 2003) . ARVC2 is an autosomal dominant entity characterized by replacement of myocytes with fibrofatty tissue leading to monomorphic VT with left bundle branch block (LBBB) pattern.
Studies in ARVC2 suggest that Ca 2+ leakage from myocardial sinus rhythm (SR) via dysfunctional RyR2 is associated with development of VTs (Tiso et al., 2001) . The incidence of ARVC2 is ≈1 in 10,000 adults in the United States. CPVT is characterized by stress-induced VT (Laitinen et al., 2003) . Roles for protein kinase A (PKA) and Ca
2+
/ calmodulin-dependent protein kinase II (CaMKII) phosphorylation and
enhancement of RyR2 open probability in these arrhythmias has been suggested (Marx et al., 2000; Valdivia, Kaplan, Ellis-Davies, & Lederer, 1995) . In patients with CPVT increased, PKA phosphorylation and leaky RyR2 channels were observed during β-adrenergic stress and exercise. Binding studies in vitro suggested that the mutant RyR2 associated with CPVT has a lower affinity for FKBP12.6 (Wehrens & Marks, 2003 (Swan et al., 1999) ; Protein: Cardiac RyR.
| CPVT2
Mutations: CASQ2 gene; Relative incidence among all variants: ≈1% or 2% of affected homozygous individuals. Heterozygous CPVT2, variant (D340stop). CASQ2 mutations are more common than previously thought and produce severe forms, and another 5% have mutations in the TRDN, CALM, TRD, ANK2, KCNJ2 genes; Gender: M/F ratio:
≈1:1; Inheritance: Autosomal Recessive (AR) (Eldar, Pras, & Lahat, 2003) . Nonsense or missense recessive form of CPVT (Lahat et al., 2001; Postma et al., 2002 
| CPVT3
Mutations: TRDN gene; Relative incidence among all variants: ≤1%;
Gender: M/F ratio: 1:1; Inheritance: malignant AR; Onset of symptoms: ≈10 years; SCD: ≈75%; Locus: 7p22-p14 (Bhuiyan et al., 2007) .
A number sign (#) is used with this entry because of evidence that CPVT3 is also caused by homozygous mutation in the TECRL gene 
| CPVT4
Mutations: ANK2 gene; Relative incidence among all variants: ≤1%;
Gender: M/F ratio: 1:1; Inheritance: AD; Onset of symptoms: ≈4 years;
SCD: ≈18%; Locus: 14q32.11; Protein: Calmodulin (CaM); Gene:
Calmodulin 1 (CALM) (Nyegaard et al., 2012 Trianin (absence).
| CPVT-related entities
Andersen-Tawil syndrome (ATS) classified as LQT type 7 (LQT7) characterized by the triad of characteristic TU wave pattern (this condition may also develop BVT, periodic flaccid paralysis and distinctive dysmorphic facial features). ATS patients may show a prolongation of the QT interval, which explains the classification as LQT7, however, QT prolongation is usually absent (Zhang et al., 2005) . In ATS1, the syndrome is associated with a loss-of-function mutation in the KCNJ2 gene which encodes the Kir2.1 inward rectifier potassium channel. ATS type 2 does not differ from ATS1 in its clinical symptoms, and specific neurological or neurocognitive defects. The phenotypes are highly variable and the penetrance is not high in the KCNJ2 related ATS (Kimura et al., 2012) . It is a phenocopy of CPVT, and both conditions appear to respond well to Na + channel antagonists, suggesting the possibility of a shared mechanism.
| LQT4
Mutations: ANK2; Incidence: ≤1%; Gender: M/F ratio: unknown;
Phenotypes: Rare variants in ANK2 are associated with various cardiac phenotypes such as atrial fibrillation (AF), atrial flutter, sinus node dysfunction, LQTS, Brugada syndrome, IVF, CPVT and hypertrophic cardiomyopathy representing "ankyrin-B syndrome."
| Clinical aspects
Major symptoms are associated with emotional stress, physical exercise or β-adrenergic agonist; including syncope, SCD, ASCD, or SCA.
Due to its potential lethal outcome, exclusion or confirmation of CPVT in children with physical and emotional syncope is mandatory.
Minor symptoms are exercised-induced palpitations, chest pain or dizziness.
Family history of SCD. Inheritance: AD, AR or sporadic. ECG with PVCs, couplets, or bigeminy. At a certain HR threshold above 100-120 bpm, isolated PVCs develop first, followed by short runs of NSVT.
With continued exercise, VT duration often prolongs and it may become sustained BVT/PVT. A classical feature is the subsequent development of BVT. Patients may develop PVT/VF without the QRS vector alternans.
| Diagnosis criteria
Heart Rhythm Society consensus statement mentions (Priori et al., 2013 ):
1. CPVT is diagnosed in the presence of a structurally normal heart and coronary arteries, normal ECG, and unexplained exercise or catecholamine-induced BVT, polymorphic PVCs or VT in individuals <40 years of age.
2.
CPVT is diagnosed in patients who have a pathogenic mutation.
3.
CPVT is diagnosed in family members of a CPVT index case with a normal heart who manifests exercise-induced PVCs or BVT/PVT.
4.
In any young person with unexplained syncope, unexplained seizures, or SCD/SCA. 3. QTc interval: normal at resting ECG (Postma et al., 2005) .
| ELECTROCARDIOGRAPHIC FEATURES
U-wave alternans:
it was observed after ventricular pacing at 160 bpm, during the recovery phase after the treadmill stress testing (TST) (Aizawa et al., 2006 corded. The onset is in the right ventricular outflow tract in more than 50% of the cases (Sumitomo et al., 2003) . The HisPurkinje system is an important source of focal arrhythmias in CPVT (Cerrone et al., 2007) . BVT is a more typical feature. It is identified as a VT characterized by a beat-to-beat alternation of the QRS axis in most of the documented runs of VT (>4 consecutive beats) (Priori et al., 2002) (Figures 2 and 3 ).
| Differential diagnosis
CPVT should be included in the differential diagnosis in children with 
ATS classified as LQT7 is characterized by the triad: QT interval pro-
longation, episodic flaccid paralysis and dysmorphic facial features.
The phenotypes are highly variable and the penetrance is not high.
Patients with KCNJ2 mutations are designated as ATS type 1;
while patients who test negative as ATS type 2. A mutation has also been reported in the KCNJ5 gene which encodes the G-protein-activated inwardly rectifying potassium channel 4 (Kir3.4) protein, causing a similar phenotype (Kokunai et al., 2014) .
Patients with this condition may also develop BVT. It is a phenocopy of CPVT, and both conditions appear to respond well to Na + channel antagonists, suggesting the possibility of a shared mecha-
nism. Currently, ATS is better defined by its characteristic T-U
wave patterns than by QT prolongation, which is usually absent (Zhang et al., 2005) .
Isolated coronary abnormalities:
It refers to a wide range of congenital abnormalities involving the origin, course, and structure of epicardial coronary arteries. By definition, these abnormalities occur in <1% of the general population. These entities, such as CPVT, may be associated with SCD during physical activities. In older children or adolescents, anginal chest pain, syncope or SCA associated with activity is suggestive of coronary artery disease (CAD). Table 1 summarizes the main differences between CPVT and isolated coronary anomalies.
ARVC:
ARVC and CPVT are rare inheritable SCD syndromes expressed in younger individuals. ARVC is characterized by a progressive fibrofatty replacement of the myocardium that predisposes to monomorphic VT with LBBB pattern while CPVT is characterized by exercise induced BVT/PVT and a structurally normal heart. A mutation in different genes causes these syndromes but, a mutation in a common gene RyR2 has been associated with both disorders and it has been suggested that CPVT and ARVC represent a phenotypic spectrum (Patel, Shah, Rampal, Shamoon, & Tiyyagura, 2015) . Some mutations in the RyR2 gene have also been identified in patients with ARVC (Bhuiyan et al., 2007) . In about 40% of patients with both ARVC and CPVT, disease-specific mutations are not identified.
5.
Hypertrophic cardiomyopathy might present with similar symptoms.
F I G U R E 2 Female, Caucasian, 20-yearold patient with recurrent syncope of uncertain etiology after physical and emotional stress; carrier of familial CPVT. QRS complexes alternans are observed with alternating RBBB and RBBB patterns. The QRS axis shifts in a beat-to-beat alternation from −60 to +120°F I G U R E 3 Typical BVT in a 7-year-old female carrier of CPVT-1 (RyR2 gene mutation). The diagnosis was made by isoproterenol infusion. Note alternant QRS complexes (RBBB and LBBB patterns) The tachycardia is due to macroreentry involving the two fascicles of the left branch. Reentry may be a possible mechanism in some cases.
| The diagnostic criteria (Priori et al., 2013)
1. Presence of a structurally normal heart, normal ECG, and unexplained exercise or catecholamine-induced BVT, polymorphic PVCs or VT in individuals <40 years of age.
Patients (proband or family member) who have a pathogenic
mutation.
3. Family members of a CPVT index case with a normal heart who manifests exercise-induced PVCs or BVT/PVT.
4.
Presence of a structurally normal heart and coronary arteries, normal ECG, and unexplained exercise or catecholamine-induced BVT, polymorphic PVCs or VT in individuals >40 years of age.
| Prognosis
The mortality rate in untreated individuals is 30%-50% by age 40. Even after initiation of medical treatment, high-risk ventricular arrhythmias were induced during exercise stress test in most RyR2-positive CPVT patients. Most fatal recurrent cardiac events occurred in patients who were noncompliant with exercise restriction and/or medical therapy.
Medical management including strict exercise restriction should be emphasized to prevent recurrent cardiac event in most RyR2-positive CPVT patients. Implantable cardioverter defibrillator (ICD) is necessary for prophylaxis of SCD because ≈30% of patients still experience
VTs that may arise in certain specific areas but the prognosis is poor.
| Animal genetic treatment
Kujala et al. using a cell model of CPVT reveals early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs). This cell model
shows aberrant Ca 2+ cycling characteristic of CPVT and in addition to DADs, it displays EADs. This cell model for CPVT provides a platform to study basic pathology, to screen drugs, and to optimize drug therapy (Kujala et al., 2012) .
| Postmortem genetic testing
Postmortem genetic testing of RyR2 should be considered as a part of the comprehensive medicolegal autopsy investigation of a sudden unexplained death case and that this potentially heritable and often elusive arrhythmia syndrome be scrutinized carefully in family members of those who experience sudden unexplained death (Tester, Spoon, Valdivia, Makielski, & Ackerman, 2004) .
| Treatment
Patients who have had an episode of VF and those who have sustained or are in hemodynamically unstable VT whilst receiving β-blockers are considered at highest risk. Younger age at CPVT diagnosis is a predictor of future events.
Electrophysiological studies are not helpful (Priori et al., 2002) .
| Removal of triggers
Patients should be cautioned against virtually all forms of vigorous physical activity. All competitive sports are prohibited for symptomatic and asymptomatic patients with typically effort-induced ECG T A B L E 1 Main differences between CPVT and isolated coronary anomalies features. In genotype-positive, asymptomatic patients without any effort-induced ECG manifestation: recreational sports with only low intensity may be allowed.
| Drugs
1. β-blockers are an effective pharmacological approach.
Unfortunately, ≈30% of patients have recurrences, and an ICD may be required. The long acting β-blocker, nadolol is preferred for prophylactic treatment of CPVT. Propranolol is also an effective medication. Carvedilol is reported to inhibit the SOICR in an HEK 293 cell culture model. Additionally, among various β-blockers, only carvedilol inhibits RyR2 activity (Zhou et al., 2011) .
2.
Verapamil has shown beneficial effects in some CPVT patients (Rosso et al., 2007) . The long-term efficacy of verapamil is controversial.
Flecainide reduced exercise-induced ventricular arrhythmias in
patients with CPVT not controlled by conventional drug therapy.
Watanabe discovered that flecainide directly inhibits RyR2 channels and prevents events in CPVT. Among the Class I anti-ar- and chronic airflow limitation with evidence of ≥20% reversibility in airway obstruction in response to inhaled salbutamol.
2.
Syncope recurrence despite maximum-dose β-blockade + flecainide;
ICD shocks recurrence or electrical storms;
4. High risk of SCD despite being asymptomatic on β-blocker therapy (Schwartz, 2014) .
ICD
Implantation of an ICD should be considered in patients in the absence of controlled optimal therapy. However, implantation of an ICD in children still has several technical problems. Moreover, inappropriate or painful shocks may increase the risk of further VTs, and electrical storms that may result in lethal events. The effectiveness of ICD shock therapy in CPVT depends on the mechanism of the rhythm treated. Shocks delivered to initiating triggered arrhythmias nearly always fail, whereas those for subsequent VF are usually effective.
| Catheter ablation
Pulmonary vein isolation is reported to be effective in some CPVT patients with AF. Purkinje cells are reported to be more arrhythmogenic than ventricular myocytes in a mutant knockout mouse model of CPVT (Kang et al., 2010) . The onset of CPVT may be initiated from Purkinje cells.
| CONCLUSION
The opportunity to perform an extensive genetic analysis allows physicians to make the correct diagnosis and to optimize clinical management. The CPVT population describes contemporary challenges related to the diagnosis and prognosis of CPVT patients. Utilizing predictive homology modeling, areas of key structural importance in 
